Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 18/20 | 0.58 |
| ▸ | JAK2 | O60674 | 11/20 | 0.58 |
| ▸ | JAK3 | P52333 | 8/20 | 0.50 |
| ▸ | TYK2 | P29597 | 6/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9953934 | 0.84 | JAK1 (0.62) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL12385291 | 0.83 | JAK1 (0.82) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL9952783 | 0.80 | GABRA1 (0.40) | JAK1JAK2 | |
| SCHEMBL2295228 | 0.80 | JAK1 (0.65) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL10281519 | 0.80 | JAK1 (0.60) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL2296233 | 0.80 | JAK1 (0.69) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL2296561 | 0.78 | JAK1 (0.62) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL2277852 | 0.76 | JAK1 (0.75) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL2363705 | 0.75 | JAK1 (0.53) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL12385566 | 0.75 | JAK1 (0.59) | JAK1JAK2JAK3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012085176-A1 | TRICYCLIC PYRAZINONE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF AS JANUS KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085176-A1 | TRICYCLIC PYRAZINONE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF AS JANUS KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-28 | — | — | WO | disclosed |